Recent studies have discovered that stem cell markers such as doublecortin-like kinase (DCLK1) and RNA modification by methyltransferase-like 3 (METTL3) also play a role in the recruitment of CXCR2+ TANs to modulate tumor immunity through the CXCL1−CXCR2 axis in CRC mouse models [103,104]. The gene discussed is CXCR2; the disease is neoplasm.